Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Milnacipran Hydrochloride). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
ইঙ্গিত ও ব্যবহার
Neocipran tablets are used to manage fibromyalgia. Neocipran is not approved for use in children.
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
Adults:
The recommended dose of Milnacipran HCI for adults is 100 mg per day, taken as 50 mg twice daily. Depending on how well the medicine works and how well it is tolerated, the dose may be built up gradually according to the following schedule: on Day 1, 12.5 mg taken once; on Days 2 to 3, 25 mg per day, taken as 12.5 mg twice daily; on Days 4 to 7, 50 mg per day, taken as 25 mg twice daily; and after Day 7, 100 mg per day, taken as 50 mg twice daily. Based on how the individual patient responds, the dose may be increased to 200 mg per day, taken as 100 mg twice daily. Doses above 200 mg per day have not been studied.
পার্শ্বপ্রতিক্রিয়া
The most commonly reported side effects are nausea, headache, constipation, dizziness, difficulty sleeping (insomnia), hot flushes, excessive sweating, vomiting, palpitations, a faster heart rate, dry mouth and raised blood pressure.
সতর্কতা ও নিষেধাজ্ঞা
Warnings & Precautions
Neocipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), similar to some medicines used to treat depression and other psychiatric disorders. Both adult and paediatric patients with depression or other psychiatric disorders may experience a worsening of their depression and/or the emergence of suicidal thoughts and behaviour (suicidality) or unusual changes in behaviour, whether or not they are taking these medicines, and this risk may persist until significant remission occurs. All patients being treated with medicines that inhibit the reuptake of norepinephrine and/or serotonin, for any indication, should be monitored appropriately and observed closely for clinical worsening, suicidality and unusual changes in behaviour, especially during the first few months of treatment or at times of dose changes, whether increases or decreases. A potentially life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions have been reported with SNRIs and SNRIs alone, including Neocipran, but particularly when taken together with serotonergic drugs (including triptans), with drugs that impair the metabolism of serotonin (including MA01s), or with antipsychotics or other dopamine antagonists. Symptoms of serotonin syndrome may include changes in mental status (e.g. agitation, hallucinations, coma), autonomic instability (e.g. tachycardia, hyperthermia), neuromuscular abnormalities (e.g. hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g. nausea, vomiting, diarrhoea). Neocipran has been associated with reports of increased blood pressure.
নিষেধাজ্ঞা
Concomitant use of Milnacipran in patients taking monoamine oxidase inhibitors (MA01s) is contraindicated. In patients receiving a serotonin reuptake inhibitor in combination with a monoamine oxidase inhibitor (MAGI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma. In clinical trials, Milnacipran was associated with an increased risk of mydriasis. It should not be used Milnacipran in patients with uncontrolled narrow-angle glaucoma.